We are actively working on preclinical research and development of cannabinoids as a promising novel treatment strategy targeting numerous diseases affecting human health. By using state of art techniques as well as by collaborating with research institutions worldwide, we are developing novel antimicrobial, cytostatic and anti-inflammatory products that are currently investigated in the preclinical research and development pipeline.

Our studies with Weill Cornell Medicine of Cornell University (New York) demonstrating antimicrobial activity were presented at the international ASM Microbe 2022 conference in Washington DC, USA and ESCMID/ASM 2022 Conference on Drug Development in Dublin, Ireland.

Moreover, in collaboration with Kaunas University of Technology, we are developing a cannabinoid-enriched prebiotic from industrial hemp byproducts. The project aims to support gut microbiota balance and overall well-being while promoting sustainability through the reuse of natural resources. By combining CBD’s biological activity with prebiotic functionality, this innovation paves the way for next-generation functional and health-promoting ingredients. Key findings have been presented and published at Riga CBM 2025.

A new study was published with Kaunas University of Technology and demonstrates that a novel double-emulsion gel system can effectively deliver and release CBD together with the probiotic Lactiplantibacillus plantarum in the gastrointestinal tract. Using an advanced in-vitro gut model, the formulation was shown to support beneficial gut bacteria, enhance microbial activity and increase the production of key metabolites such as butyrate and lactate. The results highlight the potential of CBD–probiotic combinations as an innovative functional food concept for intestinal health. Further clinical studies are planned to confirm these effects in humans.